Local safety of repeated intravitreal Ozurdex

Eye (Basingstoke)

Volumn 28, Issue 3, 2014, Pages 361-362

  Hernandez Martinez P ^a   Gallego Pinazo, R ^a   Martinez Castillo S ^a   Dolz Marco, R ^a   Diaz Llopis M ^a,b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE;

ANTERIOR EYE CHAMBER DISEASE; DISEASE COURSE; DRUG SAFETY; HUMAN; INTRAVITREAL IMPLANT; KERATOPATHY; LETTER; MEDICAL RECORD REVIEW; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY;

EID: 84896366689     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2013.265     Document Type: Letter

References (3)

1. Hernández-Martínez P, Gallego-Pinazo R, Martínez-Castillo S, Dolz-Marco R, Díaz-Llopis M. Local safety of repeated intravitreal Ozurdex. Eye 2014; 28(3): 361-362.
2. Haller JA, Bandello F, Belfort Jr. R, Blumenkranz MS, Gillies M, Heier J et al. OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117(6): 1134-1146.e3.
3. Mayer WJ, Wolf A, Kernt M, Kook D, Kampik A, Ulbig M et al. Twelve-month experience with Ozurdex for the treatment of macular edema associated with retinal vein occlusion. Eye 2013; 27(7): 816-822.